

ASX Announcement

18 March 2025

OncoSil appoints Ms Shelley Steyn as Chief Financial Officer

Sydney, Australia – 18 March 2025: The Board of pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce the appointment of Ms Shelley Steyn as Chief Financial Officer (“CFO”) with effect from 5 May 2025.

The appointment reflects OncoSil’s ongoing commitment to strengthening its leadership. As OncoSil enters a critical phase of development Ms Steyn’s appointment at Chief Financial Officer will bolster the Company’s ability to drive the Company’s strategic priorities.

Ms Steyn brings to OncoSil extensive experience with more than 17 years in senior accounting, commercial and financial analysis and audit roles.

Ms Steyn joins from Flynn Global ANZ, a division of Flynn Group LP, a multibillion-dollar franchise operator in the United States. Prior roles include with (then) ASX 200 radiopharmaceutical medical device company, Sirtex Medical (ASX:SRX); Deloitte Touche Tohmatsu and Grant Thornton.

Ms Steyn holds a Bachelor of Commerce and Postgraduate Diploma (Accounting) and is a Chartered Accountant (CA) charter holder.

This appointment follows the resignation of Mr Christian Dal Cin as CFO and Company Secretary, effective 31 March 2025. The Board would like to thank Mr Dal Cin and The CFO Solution team for their engagement and contribution to OncoSil’s business success.

OncoSil CEO, Nigel Lange said: “Shelley’s demonstrated financial capability and depth of experience across corporate development, capital management, strategic planning and financial controls and compliance will be invaluable to OncoSil as we continue to leverage our strong foundations and grow our business.

For OncoSil, this decision will help improve financial control, streamline decision-making, and lead to better long-term financial planning.

“We are entering a critical phase as we look to close recruitment on two major clinical trials and prepare for the resubmission of our marketing authorisation application to the Therapeutics Goods Association (“TGA”).

“I am delighted to welcome Shelley to our executive team and look forward to working with her to delivering on our strategy and the promise of the OncoSil™ single-use internal radiation device to treat patients with locally advanced unresectable pancreatic cancer.”

Authorisation & Additional Information

This announcement was authorised by the Board of OncoSil Medical Limited.

For further information, please contact:

| | | |
|--|--|---|
| Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043 | Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254 | Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699 |
|--|--|---|

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>